A longitudinal, population based study of life expectancy in multiple sclerosis was performed in the county of M0re and Romsdal, Norway during the period 1950-84. A total of 251 patients with multiple sclerosis (110 men, 141 women, mean age at onset of disease 33-6 years) were included. The mean follow up time was 18-1 years. At the end of the study period 70 patients had died. Fifty four (77-1%) of these had multiple sclerosis as the underlying or contributing cause of death on the death certificates. Young age at onset, initial remitting clinical course, and the presence of sensory symptoms at onset were significantly associated with longer survival. (J Neurol Neurosurg Psychiatry 1995;58:417-42 1) 
probable (43 patients), and possible multiple sclerosis (66 patients). The mean age at onset was 33-6 (range 14-0-61-0) years. The patients were divided into remitting (including remitting progressive) and primary progressive categories based on the initial clinical course of the disease. The disease development was classified as remitting when there was a minimum duration of complete or partial remission of at least six months. The criterion for progressive disease was continuing deterioration without remission, whatever the rate of decline. The manifestations at onset of disease, the time of diagnosis, and the clinical course from initial symptoms to diagnosis were assessed retrospectively. The Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Mere and Romsdal, Norway paraesthesiae (table 2) . The other clinical ifestation were not statistically significant in manifestations at onset were not significantly the multivariate analyses. The relations related to prognosis. The results were similar between survival and age at onset, clinical in the survival analyses with multiple sclerosis course, and paraesthesiae as initial symptom as underlying or contributing cause of death were similar in the analyses with multiple scleused as end point (tables 1 and 2). rosis specific death used as endpoint. Survival The analyses were repeated with only defi-for the most recent period was, however, nite and probable cases included eliminating slightly poorer, although the low numbers any bias introduced by including cases with resulted in imprecise estimates (table 3) . possible multiple sclerosis. Sixty patients were dead out of 185 definite and probable cases. The results in the two analyses were largely Discussion comparable, and in the multivariate analyses The present study included all patients with the possible cases were excluded.
multiple sclerosis who have come to medical Age at onset, clinical course, and paraes-attention in the county of More and Romsdal, thesiae were significantly related to survival in Norway during the 35 year period. A comthe multivariate analysis (table 3) . The plete and long term follow up was obtained. longest survival was in patients with young None of the patients included in this study age at onset, remitting course of disease, and were treated by immunosuppressive drugs. paraesthesiae as the initial symptom. The Therefore, they represent all cases in effects of sex and ataxia as initial clinical man-a defined population and should reflect the natural history of multiple sclerosis in a high risk area in Scandinavia. Mortality has been recorded until 1 July 1991.
Age at onset of multiple sclerosis was a strong prognostic indicator, with low age at onset of the disease having the most favourable prognosis as shown both in the univariate and the multivariate analyses. The results corroborate several studies as reviewed by Weinshenker and Ebers,'9 including a recent population based Canadian study. 20 The duration of multiple sclerosis from onset to death from multiple sclerosis is on average shorter for those with late rather than early onset. Patients with late onset have, however, experienced at least 40 years without symptoms of multiple sclerosis. The survival time is certainly longer for young patients, but the prognosis as judged from the disruption of the normal pattern of life from an early age may indeed be worse.2' The shorter survival among patients with a high age at onset may be a reflection of the shorter life expectancy among older patients, independently of the disease; however, in survival analyses including only multiple sclerosis as the underlying cause of death as end point, the statistically significant relation between age at onset and life expectancy remained. Thus the age effect on life expectancy may represent a real biological effect of the disease. In previously published studies'4 20 a significant association between age at onset and entry into moderate or severe residual disability has been found, thus indicating a similar possible biological interplay of age at onset and prognosis. A relative survival analysis that takes into account the mortality in the general population is necessary to consider this issue.
The apparent worsening of the prognosis between 1970 and 1984 is unexpected. The methods of investigation, the record keeping, and the catchment area were identical throughout the study. Death is most often a late event in multiple sclerosis. Due to a short observation time in the most recent cohort, the results may be biased towards the worst cases in the latest period. The diagnostic delay in more benign cases from onset to diagnosis of disease may also contribute to a higher frequency of severe cases. The observed prognostic effect is stronger in the multiple sclerosis specific cohort, and might indicate a more comprehensive classification of deaths from multiple sclerosis in the most recent period. Also, some under-reporting of deaths from multiple sclerosis can be assumed in the previous periods.
An initial remitting course of the disease indicated a favourable prognosis. Thus our study confirms the results from similar investigations.'3 The advantageous outlook for a longer survival in patients with definite and probable multiple sclerosis with an initial, remitting clinical course remained statistically significant when all causes of death were taken as the end point as well as when multiple sclerosis as underlying or contributing cause of death was the end point. Age at onset is related to course of disease, but age at onset and course of disease showed independent effects on prognosis in the multivariate analysis.
Initial clinical manifestations such as symptoms from the sensory system and the appearance of ataxia showed significance in the univariate analyses independent of the choice of endpoint. Consistent with other reports7 9" 22 paraesthesiae were associated with a favourable prognosis. Ataxia indicated a poorer prognosis, although this was not significant in the multivariate model. The adverse effect of ataxia, interpreted as a combination of dysfunctions in strength and coordination, corroborates earlier reports indicating that pyramidal (motor) and cerebellar findings are generally ominous.78 10 The presence of multiple symptoms at onset did not reach statistical significance as a prognostic factor in this study.
When death, irrespective of cause, was taken as the end point in the univariate survival analysis, sex was significant indicating that women fared better than men. Similar results were obtained when death with multiple sclerosis as the underlying and contributing cause of death was taken as the end point, although these results were not significant in the multivariate analysis (table 3) . These results are consistent with results from previous studies indicating that the survival rate for men with multiple sclerosis is lower than for women,23 24 although others have failed to show any influence of sex on survival.'2 13 The life expectancy in general in the Norwegian population shows a lower survival rate for men than women. Our results, showing a difference between men and women, might be a reflection of this fact.
In conclusion, the age at onset of multiple sclerosis and the initial clinical course of disease were the strongest predictors for survival in this study. Paraesthesiae were the only clinical manifestations at onset with a significant effect on duration of survival. Acknowledging the interindividual variability in the natural course of the disease, the prognostic factors identified in this study might be of some help when advising newly diagnosed patients with multiple sclerosis on questions regarding the future. 
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